95 related articles for article (PubMed ID: 21029998)
1. Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease.
Fillit H; Hofbauer RK; Setyawan J; Tourkodimitris S; Fridman M; Pejović V; Miller ML; Erder MH; Lyketsos C
J Am Med Dir Assoc; 2010 Nov; 11(9):636-644. PubMed ID: 21029998
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
Hellweg R; Wirth Y; Janetzky W; Hartmann S
Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
5. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
[TBL] [Abstract][Full Text] [Related]
6. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
7. The use of acetyl cholinesterase inhibitors and memantine in nursing home residents.
Gorus E; Van Puyvelde K; Corremans V; Mets T
Acta Clin Belg; 2011; 66(5):361-6. PubMed ID: 22145270
[TBL] [Abstract][Full Text] [Related]
8. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece.
Förstl H; Stamouli SS; Janetzky W; Galanopoulos A; Karageorgiou C; Tzanakaki M
Dement Geriatr Cogn Disord; 2011; 32(4):267-72. PubMed ID: 22237255
[TBL] [Abstract][Full Text] [Related]
9. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
11. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
[TBL] [Abstract][Full Text] [Related]
13. Treated Behavioral Symptoms and Mortality in Medicare Beneficiaries in Nursing Homes with Alzheimer's Disease and Related Dementias.
Huang TY; Wei YJ; Moyo P; Harris I; Lucas JA; Simoni-Wastila L
J Am Geriatr Soc; 2015 Sep; 63(9):1757-65. PubMed ID: 26310959
[TBL] [Abstract][Full Text] [Related]
14. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.
Wilkinson D; Wirth Y; Goebel C
Dement Geriatr Cogn Disord; 2014; 37(1-2):71-85. PubMed ID: 24107324
[TBL] [Abstract][Full Text] [Related]
15. The CITIMEM study: A pilot study. Optimizing pharmacological treatment in dementia.
Gareri P; Cotroneo AM; Orsitto G; Putignano S
Arch Gerontol Geriatr; 2020; 89():104073. PubMed ID: 32447126
[TBL] [Abstract][Full Text] [Related]
16. [Memantine].
Molinuevo JL
Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
[TBL] [Abstract][Full Text] [Related]
17. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
Tariot PN
J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
[TBL] [Abstract][Full Text] [Related]
18. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
19. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
[TBL] [Abstract][Full Text] [Related]
20. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]